Zacks Investment Research on MSN

Novavax grants license for use of Matrix-M adjuvant to Pfizer

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...

Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Nasdaq

Novavax Expands Collaboration And License Agreement With Sanofi On Use Of Matrix-M Adjuvant

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...

Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.